Actavis Group PTC

Actavis Group PTC is a pharmaceutical entity that functions as a core intellectual property and regulatory hub within the generics division of Teva Pharmaceutical Industries. Originally a central component of the Icelandic Actavis Group, the entity was acquired by Teva in 2016 as part of a multi-billion dollar transaction to consolidate global generics leadership. The company specializes in the development, patent litigation, and registration of high-quality generic versions of branded pharmaceuticals across a wide array of therapeutic areas. Its operations ensure the continued availability of affordable medication options in global markets, leveraging extensive expertise in bioequivalence and complex formulation.